This memo highlights the patient benefits, cost savings and improved supply security associated with proactively switching eligible 2L patients on PIs to DTG-based regimens.
Optimizing 2L HIV Treatment with DTG-based Regimens
Updated: Jan 6, 2022
top of page
A framework to support new product introduction in national health systems
bottom of page
Comments